Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
QuidelOrtho ( (QDEL) ) has shared an update.
On March 18, 2026, QuidelOrtho announced that Chief Legal Officer and Corporate Secretary Michelle A. Hodges plans to retire from her roles effective March 23, 2026, with a structured transition agreement in place. She will remain with the company for up to six months to transition her duties and then serve as special advisor to the CEO for up to 24 months, retaining salary, reduced over time, and continued eligibility for benefits and equity vesting during this period.
As part of its board-led succession planning, QuidelOrtho appointed Nathaniel “Nate” Sisitsky as Chief Legal Officer and Corporate Secretary effective March 23, 2026. Sisitsky, a veteran legal executive with more than 25 years of experience in life sciences and medtech, previously held top legal roles at STAAR Surgical, NuVasive and CareFusion, and is expected to reinforce QuidelOrtho’s legal, compliance and governance capabilities as it pursues long-term growth and navigates complex regulatory and transformational initiatives.
The leadership transition underscores QuidelOrtho’s emphasis on continuity and governance stability at a time of ongoing strategic evolution in the diagnostics sector. By retaining Hodges in an advisory role while installing a seasoned successor, the company aims to mitigate transition risk, maintain momentum on strategic and regulatory matters, and signal to investors and other stakeholders that its legal function remains tightly aligned with its growth and transformation agenda.
The most recent analyst rating on (QDEL) stock is a Sell with a $14.00 price target. To see the full list of analyst forecasts on QuidelOrtho stock, see the QDEL Stock Forecast page.
Spark’s Take on QDEL Stock
According to Spark, TipRanks’ AI Analyst, QDEL is a Neutral.
The score is held down primarily by weak financial performance (large losses, higher leverage, and reduced cash generation) and bearish technicals (price well below key moving averages with negative momentum). This is partially offset by a more constructive earnings-call outlook, with 2026 guidance pointing to modest margin improvement, better free cash flow, and gradual deleveraging.
To see Spark’s full report on QDEL stock, click here.
More about QuidelOrtho
QuidelOrtho Corporation (Nasdaq: QDEL) is a leading global provider of in vitro diagnostic solutions, with expertise spanning clinical chemistry, immunoassay, immunohematology and molecular testing. The company focuses on delivering fast, accurate and reliable diagnostic results across point-of-care, hospital, laboratory and clinic settings to support informed medical decision-making and improved patient outcomes.
Building on a legacy of innovation in diagnostics, QuidelOrtho works closely with healthcare providers worldwide to connect data-driven insights with practical solutions. Its market positioning as a global diagnostics leader underpins its strategy to advance technologies that power a healthier future and strengthen its role in critical areas of global healthcare delivery.
Average Trading Volume: 1,271,489
Technical Sentiment Signal: Sell
Current Market Cap: $1.13B
See more insights into QDEL stock on TipRanks’ Stock Analysis page.